Saturday, November 14, 2026

Less Than Two Hours Before The Market Open, Illumina Is Down By 5%

ViaNews Editorial Team

January 16, 2024

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Less Than Two Hours Before The Market Open, Illumina Is Down By 5%

(VIANEWS) - The NASDAQ opens in less than two hours and Illumina's pre-market value is already 5.49% down.

Illumina's last close was $138.04, 42.13% under its 52-week high of $238.55.

The last session, NASDAQ ended with Illumina (ILMN) sliding 2.11% to $138.04. NASDAQ jumped 0.02% to $14,972.76, following the last session's upward trend on what was a somewhat positive trend exchanging session.

About Illumina

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Earnings Per Share

As for profitability, Illumina has a trailing twelve months EPS of $-7.1.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -17.82%.

Sales Growth

Illumina's sales growth is negative 1% for the current quarter and negative 3.4% for the next.

Yearly Top and Bottom Value

Illumina's stock is valued at $138.04 at 08:24 EST, way below its 52-week high of $238.55 and way higher than its 52-week low of $89.00.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 4.46B for the twelve trailing months.

Volume

Today's last reported volume for Illumina is 1564798 which is 42.29% below its average volume of 2711710.

More news about Illumina (ILMN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com